{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:45:09Z","timestamp":1790516709077,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00109","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T23:29:50Z","timestamp":1551914990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders"],"prefix":"10.3389","volume":"9","author":[{"given":"Jennifer L.","family":"Crombie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1038\/emm.2014.82","article-title":"EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management","volume":"47","author":"Ok","year":"2015","journal-title":"Exp Mol Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt's lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","article-title":"EBV-associated lymphoproliferative disorders: classification and treatment","volume":"13","author":"Carbone","year":"2008","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp Mol Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.coviro.2013.04.005","article-title":"The pathogenesis of Epstein-Barr virus persistent infection","volume":"3","author":"Thorley-Lawson","year":"2013","journal-title":"Curr Opin Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-319-22822-8_13","article-title":"The role of EBV in the pathogenesis of diffuse large B cell lymphoma","volume":"390","author":"Healy","year":"2015","journal-title":"Curr Top Microbiol Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ajh.24370","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/10428190802311417","article-title":"Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas","volume":"49","author":"Cohen","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt's lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1634\/theoncologist.11-4-375","article-title":"Burkitt's lymphoma: clinicopathologic features and differential diagnosis","volume":"11","author":"Ferry","year":"2006","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct Target Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1073\/pnas.0608745104","article-title":"Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9","volume":"104","author":"Parroche","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","article-title":"How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa","volume":"132","author":"Gopal","year":"2018","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am J Surg Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1399-0039.2007.00891.x","article-title":"Immunosenescence: deficits in adaptive immunity in the elderly","volume":"70","author":"Hakim","year":"2007","journal-title":"Tissue Antigens"},{"key":"B27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/annonc\/mdu556","article-title":"EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?","volume":"26","author":"Hong","year":"2015","journal-title":"Ann Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2007-01-067769","article-title":"The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/ajcp\/103.6.748","article-title":"Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin","volume":"103","author":"Weissmann","year":"1995","journal-title":"Am J Clin Pathol."},{"key":"B36","first-page":"936","article-title":"Lymphoma: risk and response after solid organ transplant","volume":"24","author":"Jacobson","year":"2010","journal-title":"Oncology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med."},{"key":"B39","first-page":"453","article-title":"Post-transplant lymphoproliferative disorders In","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed.","author":"Swerdlow","year":"2017"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ajt.12196","article-title":"Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"13","author":"Morscio","year":"2013","journal-title":"Am J Transplant."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/10428194.2016.1205742","article-title":"Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules","volume":"58","author":"Kampers","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Uhlin","year":"2014","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2013.07.013","article-title":"Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/clinids\/20.5.1346","article-title":"Pretransplantation assessment of the risk of lymphoproliferative disorder","volume":"20","author":"Walker","year":"1995","journal-title":"Clin Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1200\/JCO.2013.50.3326","article-title":"Validation of prognostic scores in post-transplantation lymphoproliferative disorders","volume":"31","author":"Dierickx","year":"2013","journal-title":"J Clin Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1182\/blood-2010-11-320481","article-title":"Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders","volume":"117","author":"Ouyang","year":"2011","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1480767","article-title":"Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation","author":"Kinch","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B69","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant."},{"key":"B70","doi-asserted-by":"publisher","first-page":"509296","DOI":"10.1155\/2012\/509296","article-title":"Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies","volume":"2012","author":"Ghosh","year":"2012","journal-title":"Adv Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"van Esser","year":"2002","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/bmt.2013.84","article-title":"Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab","volume":"48","author":"van der Velden","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B74","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cmi.2015.02.002","article-title":"Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey","volume":"21","author":"San-Juan","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"B75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5152\/eurjrheum.2016.032","article-title":"Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept","volume":"4","author":"Klein","year":"2017","journal-title":"Eur J Rheumatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00000478-200205000-00009","article-title":"Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms","volume":"26","author":"Abruzzo","year":"2002","journal-title":"Am J Surg Pathol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ajh.21753","article-title":"Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis","volume":"85","author":"Adams","year":"2010","journal-title":"Am J Hematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?","volume":"32","author":"Natkunam","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T23:29:52Z","timestamp":1551914992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":79,"alternative-id":["10.3389\/fonc.2019.00109"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00109","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"article-number":"109"}}